APIActive Pharmaceutical Ingredients

White Paper

Product Alert – Pazopanib API

Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-α and -β, fibroblast growth factor receptor (FGFR)-1 and -3, cytokine receptor (Kit), interleukin-2 receptor-inducible T-cell kinase (Tck), lymphocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor tyrosine kinase (cFms) [2].

In vitro - Pazopanib inhibited ligand-induced autophosphorylation of VEGFR-2, Kit, and PDGFR- beta receptors.
In vivo - Pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation in mouse lungs, angiogenesis in a mouse model, and the growth of some human tumor xenografts in mice.

Dr. Reddy's API Offering

We offer crystalline polymorph form.
An early mover in API development and filled the USDMF in March 2021. In addition, we are planning to file the DMFs in China, Japan, Brazil, Europe, and Korea.
Particle size distribution (PSD) - D (90) < 50 µ, based on customer requirements, we can offer lower particle or customized sizes.

To know more about our API offerings, please read the Tech sheet on Pazopanib API by filling the contact form below.

Explore other Whitepapers:

Know More

Email us: api@drreddys.com
+91 40 49002222

Download Now

Please fill the Contact form below in order to view the white paper

* I agree and accept the Privacy Policy and Terms of Use of this website.

Email us: api@drreddys.com | +91 40 49002222

Disclaimer

No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.